26 July 2023 Oryzon announces completed patient recruitment in the PORTICO Phase IIb trial of vafidemstat in Borderline Personality Disorder
24 July 2023 ORYZON reports financial results and corporate updates for half-year ending June 30, 2023
5 July 2023 Positive aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
21 June 2023 Positive preclinical data of ORY-4001 for the treatment of Charcot-Marie-Tooth (CMT) disease presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
30 May 2023 ORYZON to present positive preclinical efficacy data of ORY-4001 in Charcot-Marie-Tooth (CMT) disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
17 May 2023 ORYZON to present trial in progress Phase Ib FRIDA study at the upcoming 2023 ASCO annual meeting